Enliven Therapeutics Inc
enliventherapeutics.comEnliven Therapeutics Inc (NASDAQ: ELVN) is a clinical-stage biopharmaceutical company that researches and develops small molecule drug candidates, with its lead program ELVN-001 in active clinical trials as of the 10-K filed March 3, 2026. The company has no approved products and generates no product revenue, funding operations through capital raises rather than commercial sales. Enliven relies substantially on third-party contract research organizations, manufacturers, and consultants to execute research, clinical development, regulatory, and manufacturing activities. Richard Fair serves as President and Chief Executive Officer, as noted in the FY2025 10-K filing.
Products & Services
Lead clinical candidate ELVN-001, referenced as an active development program in the 10-K filed March 3, 2026. Additional early-stage research programs are referenced but not named in the available filing excerpts.
Revenue Model
Enliven Therapeutics generates no product revenue as of FY2025. The company is pre-commercial and funds operations through equity financing. Future revenue, if any, would depend on regulatory approval and commercialization of product candidates such as ELVN-001.
Customers & Markets
No commercial customers as of FY2025. Target end market, based on clinical development activity, is oncology or a related therapeutic area, though the available filing excerpts do not specify the disease indication explicitly.
Geographic Exposure
Operations referenced in the United States, with clinical trial activity potentially spanning EU and UK jurisdictions based on data privacy compliance disclosures in the FY2025 10-K.
Financial Snapshot
Loading...
